Amarin Corporation plc (ADR) Stock Xetra
Equities
EH3A
US0231112063
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Sales 2024 * | 202M 188M | Sales 2025 * | 215M 200M | Capitalization | 350M 325M |
---|---|---|---|---|---|
Net income 2024 * | -70M -65M | Net income 2025 * | -64M -59.43M | EV / Sales 2024 * | 1.52 x |
Net cash position 2024 * | 43.92M 40.78M | Net cash position 2025 * | 159M 147M | EV / Sales 2025 * | 0.89 x |
P/E ratio 2024 * |
-4.83
x | P/E ratio 2025 * |
-5.13
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.48% |
Latest transcript on Amarin Corporation plc (ADR)
Managers | Title | Age | Since |
---|---|---|---|
Patrick Holt
CEO | Chief Executive Officer | 52 | 23-07-17 |
Thomas Reilly
DFI | Director of Finance/CFO | 52 | 22-06-19 |
Compliance Officer | 55 | Nov. 14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Louis Sterling
BRD | Director/Board Member | 45 | 23-02-27 |
Odysseas Kostas
CHM | Chairman | 49 | 23-02-27 |
Keith Horn
BRD | Director/Board Member | 66 | 23-02-27 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 108B | |
+10.87% | 104B | |
+1.28% | 22.33B | |
-13.14% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.66% | 17.64B | |
+3.75% | 14.05B | |
+36.70% | 12.51B |
- Stock Market
- Equities
- AMRN Stock
- EH3A Stock